Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with coronavirus disease-2019 (COVID-19) referring to Sina and Imam-Khomeini Hospitals in 2020
Phase 4
Recruiting
- Conditions
- COVID-19.corona virus disease 2019U07.1
- Registration Number
- IRCT20151113025025N3
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients who have suggestive signs of COVID-19 in their chest computed tomography scan, reported by a radiologist
Patients consuming angiotensin converting enzyme-inhibitors or angiotensin receptor blocker
Exclusion Criteria
Uncontrolled hypertension with systolic blood pressure more than 180 or diastolic more than 120
Past history of congested heart failure or arrhythmia with various severity
Sensitivity to the newly-prescribed medications
History of severe asthma
History of known depression
Consuming medications with interactions such as lithium, antiepileptic drugs, chemotherapy
Pregnancy
Patient unwillingness to enter the study
Patients whose prognosis is influenced by another disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death. Timepoint: 3 months. Method of measurement: Number of deceased patients.
- Secondary Outcome Measures
Name Time Method ICU admission. Timepoint: 6 months. Method of measurement: Number of deceased patients.